About Us


Click on the name to see their biography.

Dr. Pavel Hamet, OQ, FRCP(C), FRSM, FAHA, FCAS

Founder, President and Chief Executive Officer of Prognomix Dr. Pavel Hamet is recognized internationally for his contribution to the field of diabetes, hypertension and genetics and is a member of the management of the largest-ever clinical trial in diabetes called ADVANCE (Lancet 2007, N Engl J Med 2008, Diabetes Care 2009) which is the source of the clinical data for Prognomix. Dr. Hamet is the Canada Research Chair in Predictive Genomics. He is Professor of Medicine at the Université de Montréal, Adjunct Professor of Experimental Medicine at McGill University, and Visiting Professor at the First Faculty of Medicine at Charles University, Prague, Czech Republic. He founded and directed the Centre Hospitalier de l’Université de Montréal’s Research Centre (CRCHUM) from 1996 to 2006. He is currently Chief of gene medicine services at the CHUM. Born in the Czech Republic, Dr. Hamet received his Doctorate in Medicine in 1967 from Charles University, a PhD in Experimental Medicine from McGill University in 1972, and a CSPQ in Endocrinology from Université de Montréal in 1974. He is a fellow of the Canadian Academy of Health Sciences since 2004. Dr. Hamet is the author or co-author of over 500 scientific publications and holds several international patents. His major scientific contributions are in the areas of hypertension, diabetes and cardiovascular diseases, using approaches that range from bench to bedside to population health. Active in many societies, he is President-elect of the International Society of Pathophysiology. He was President of the Canadian and Quebec Hypertension Societies and General-Secretary of the International Society of Hypertension. He has received many honors, including the Harry Goldblatt Award from the American Heart Association (1990), Honorary Professor at the Shanghai II Medical University in China (1994), the J.E. Purkyne Golden Medal by the Czech Academy of Sciences (1994), the Distinguished Scientist Award from the Canadian Society for Clinical Investigation and the Achievement Award from the Canadian Cardiovascular Society (1996). the Wilder Penfield Award from the Government of Québec (2001), Honorary Member of the Czech Medical Academy, and the Michel Sarrazin Prize by the Club de recherches cliniques du Québec, the Canadian Hypertension Society Distinguished Service Award (2005). He is a member of the Academy of Great Montrealers (2006). In 2008, Dr Hamet was named as an Officer of the Ordre national du Québec and he received the Okamoto Award by the Japan Vascular Disease Research Foundation, the Masaryk Award from the Czech and Slovak Society in Canada and an award from the Russian Society of Cardiology and the Russian Antihypertensive league and received from the CHUM Fundation «le Prix Hommage» to underline his remarkable career (2009). He is co-editor of the Journal of Hypertension and member of Collège International de Recherche Servier. Since 2010 he is a member of the Board of Directors of the Société francophone du diabète.

Dr. Johanne Tremblay, PhD, FCAHS, FAHA
Vice-President and CSO

Johanne Tremblay is co-founder and Vice-President and Chief scientific officer of Prognomix Inc. She is Professor of Medicine and chief of the Laboratory of Cell Biology of Hypertension and of the Cardiometabolic Axis at the CHUM Research Centre of the University of Montreal. Dr. Tremblay received her PhD in Biomedical Sciences from University of Montreal in 1982. After two years of post-doctoral fellowship supported by the Heart and Stoke Foundation of Canada at the Clinical Research Institute of Montreal and Vanderbilt University, in Nashville, USA, she came back to the University of Montreal and was awarded a scholarship from Fonds de la recherche en santé du Québec, FRSQ from 1984-1996. She received her first Medical Research Council grant in 1984 and has been funded continuously since by the Canadian Institutes of Health Research, CIHR. In 1993, she received the Young Investigator Award from the Canadian Hypertension Society and the Prix du Jeune Chercheur from the Société Québécoise d'Hypertension in 1994. She acted as Chair of the Multidisciplinary Research Groups and Scholarship committees of FRSQ, deputy Chair of the Molecular Biology study section at the Canadian Heart and Stroke Foundation and is currently the Chair of the Cardiovascular System B Committee of the CIHR. In 2002, she was President of the Club de Recherches Cliniques du Québec. In 2003, she was President of the Canadian Hypertension Society and she was President of the Société Québécoise d'Hypertension Artérielle from 2004 to 2006 and received the Prix reconnaissance from this Society in 2010. She is author or co-author of over 250 scientific publications and holds several patents and was member of the editorial Boards of Journal of Hypertension, American Journal of Hypertension and the Canadian Journal of Cardiology. She is Fellow of the Canadian Academy of Health Sciences and the American Heart Association and Member of the Scientific Committee of the Collège International de Recherche Servier. Her expertise includes the genetics of cardiovascular diseases.

Normand Balthazard,

Normand Balthazard, CEO of Prognomix Inc. Past Founder and President of BioCapital in 1990, an Investment Fund in Biotech listed on the Toronto TSX in 1997 and acquired by an Institutional Investors in 2001 for a realized IRR of 19.75% to investors. Over the years, he has raised more than $200 million for the BioCapital VC Fund and for portfolio companies. He was the founder of Cryocath (CCT:TSX acquired by Medtronics) and Conjuchem (CJC:TSX) and also lead investors in the start-up phases of Biomatrix (acquired by Genentech), Methylgene (MYG:TSX), Neurochem (NRM:TSX), Labopharm (acquired by Paladin), Intellivax (Acquired by ID Biomedical and subsequently by Chiron), Vasogen (VAS:TSX) and Cardiome Pharma (COM:TSX). He was also a key investor in the private financing of Paladin (PDL:TSX) and Icagen (acquired by Pfizer). Mr. Balthazard received an Honour from Fondation Armand Frappier in 1996 for his contribution to the biotech industry in Québec and the Grand Prix Financier du Québec in 2001. Mr. Balthazard was also an Advisor to Genome Canada with the mandate to prepare a $2 billion strategic plan for the 2010–2020 and structure a new $75 million funding program for private organizations. He was also Senior Vice-President KPMG Corporate Finance, specialized in M&A for mid-size companies.